EndoQuest Robotics vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Flexible endoluminal surgical robot for GI procedures. $232M raised (Series D-2, Jul 2025); FDA-approved PARADIGM pivotal trial underway at Mayo Clinic, Cleveland Clinic, and Brigham and Women's.
About
EndoQuest Robotics is developing the Endoluminal Surgical (ELS) System, a flexible robotic platform designed for minimally invasive gastrointestinal surgery performed entirely through natural orifices — without external incisions. The system is engineered for therapeutic endoscopists and colorectal surgeons performing complex upper and lower GI procedures, including endoscopic submucosal dissection (ESD). EndoQuest closed a Series D-2 round in July 2025, co-led by Crescent Enterprises and Dr. Fred Moll (founder of Intuitive Surgical), bringing total funding to $232M. The FDA-authorized PARADIGM pivotal trial is actively enrolling 50 patients at five leading U.S. institutions — including Mayo Clinic, Cleveland Clinic, Brigham and Women''s Hospital, AdventHealth, and HCA Healthcare — with first ESD procedures completed in 2025. The FDA has cleared the final stage of the trial.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
EndoQuest Robotics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.